Category: news
-
CellGENTherapies attracted by VIB and KUL
CellGENTherapies is attracted by the VIB and the Katholieke Universiteit Leuven (Prof Dieter Lambrechts) to produce a lipid nanoparticle RNA cancer vaccine using the Galsome technology developed by Ghent Research Group on Nanomedicines (Prof Stefaan De Smedt and Dr Ine Lentacker) for a clinical trial in patients with hepatocellular carcinoma (PI prof Jeroen Dekervel, UZLeuven).…
-
Grant for phase I clinical trial evaluating a personalized mRNA-LNP vaccine in NSCLC
Prof Bart Vandekerckhove, head of the GMP unit ‘CellGENTherapies’ of Ugent and UZ Gent, has received an important grant of €790K from ‘the Stichting Tegen Kanker (STK)’ and ‘Kom op tegen Kanker (KOTK)’, both Belgians associations funding research to improve cancer outcome. The grant will be used to setup a Phase I clinical trial of…
-
The novel Nobel I building welcomes the large new GMP unit ‘CellGENTherapies’ by 2026
On the UZ Gent campus, a new GMP unit is being built, covering no less than 1000 m2 and meeting the latest quality requirements. The new GMP unit will be fully operational by the end of 2026. With the new facilities, the University Hospital of Ghent (UZ Gent) continues to facilitate research into innovative applications…
-
Phase 1 clinical trial evaluating a neoantigen-targeted dendritic cell vaccine (Neo-mDC) in lung cancer patients
We are excited to share the publication by Ingels J., De Cock L.,et al.in Cell Reports Medicine, reporting the results of a phase 1 clinical trial evaluating a neoantigen-targeted dendritic cell vaccine (Neo-mDC) in lung cancer patients. CellGenTherapies had a pivotal role in advancing this highly personalized cancer vaccine to its first-in-human clinical trial. Neo-mDC…
-
The City of Ghent supports the GMP facility catalyzing scientific innovation
The City of Ghent supports future-oriented economic clusters, focusing on the present spearheads biotech & life sciences, cleantech, healthtech and digitech, in their further growth. For the further development of these ecosystems, both locally and internationally, the City of Ghent has established a spearhead fund of €4.9 million. The GMP facility ‘CellGENTherapies’ at University hospital…
-
EFRO, FWO and UZGent are funding new cleanroom facility for ATMP production at University Hospital Ghent
Headed by prof. Bart Vandekerckhove, in 2024 “CellGENTherapies”, the GMP unit of University Hospital of Ghent (UZ Gent) and the University of Ghent (Ugent), has received €4.6 million external funding from Europees Fonds voor Regionale Ontwikkeling (EFRO RNAvance), Fonds voor Innoveren en Ondernemen (FIO) and Fonds voor Wetenschappelijk Onderzoek (FWO-Hercules). This budget supplemented with an…